Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

Introduction: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheles...

Full description

Bibliographic Details
Main Authors: Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo
Format: Article
Language:English
Published: AboutScience Srl 2022-09-01
Series:Global & Regional Health Technology Assessment
Subjects:
ALK
Cost-benefit
Cost-effectiveness
Economic evaluation
Lung cancer
Non–small cell lung cancer
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/2449

Internet

https://journals.aboutscience.eu/index.php/grhta/article/view/2449

Similar Items